Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2012

View Archived Issues

Discovery of small-molecule, brain-penetrable agents for Parkinson's disease

L-Arginine evaluated in severe falciparum malaria

Kyowa Hakko Kirin patents novel calcium channel ligands

Achaogen discloses new agents for Gram-negative bacterial infections

Lilly stops one of three phase III tabalumab trials in rheumatoid arthritis

Phase I trial of MM-141 commences in advanced solid tumors

Encouraging data reported from phase III study of Reolysin in head and neck cancers

Gilead Sciences signs definitive agreement to acquire YM BioSciences

ArQule treats first patient in phase I trial of ARQ-087

First patient dosed in phase II galeterone trial

Eisai and UCL partner to develop new treatments for neurological diseases

FDA accepts NDA for Pfizer and Ligand's BZA/CE

Targeted delivery of proteins across BBB disclosed by U.S. team

Roche presents novel hormone-sensitive lipase inhibitors

Researchers at Roche disclose new protein kinase inhibitors

Bionomics and Merck KGaA present new potassium channel blockers

Bay-846, a potential new treatment for malignant brain tumors

AXL inhibitors show efficacy in leukemia

Bionomics nominates new candidate for treatment of Alzheimer's disease

Novel inhibitor of IDH1/2 shows therapeutic potential in the treatment of AML

Japanese researchers present novel biomarkers of sublingual immune therapy

FDA approves GSK's raxibacumab for inhalational anthrax

Novel class of compounds discovered to overcome antibacterial resistance

Biotron's BIT-225 completes proof-of-concept trial in HIV

EMA committee adopts negative opinion on MAA for Kynamro in HoFH

Vanda's Fanaptum receives negative opinion from EMA

EMA committee recommends approval of Selincro for alcohol dependence

FDA approves Novartis' Signifor for treatment of Cushing's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.